Newsroom

Title
MegaPro Biomedical Achieves Preliminary Alignment with U.S. FDA on Phase III Clinical Development Plan for MPB-1523
MegaPro Biomedical's Cell Therapy Product MPB‑2354 Selected as Top 8 Finalist in the Healthcare Sector at SelectUSA Tech
MegaPro Biomedical Announces On‑Track Progress of Global Phase III Clinical Trial Program for MPB‑1523
MegaPro Biomedical Announces Acceptance of Clinical Study Report for MPB‑1734 Phase 1/2a Trial by Taiwan FDA
MegaPro Biomedical’s Dual Technology Platforms Enter Value‑Harvesting Phase
MegaPro Biomedical Announces Submission of Pre‑IND Meeting Request for Phase III Clinical Trial of MPB‑1523
MegaPro Biomedical completed capital increase and introduced new strategic partners
MPB-1734 new dosage form anticancer drug has passed the US FDA clinical I/IIa IND application
The company passed the approval of the Industrial Bureau of the Ministry of Economic Affairs for the second time as a new biotechnology drug company
MegaPro Biomedical Held a Pre-Emerging Stock Market Investors Briefing on Oct.14, 2021